NASDAQ:ZVRA Zevra Therapeutics Q3 2025 Earnings Report $10.48 -0.21 (-1.92%) Closing price 03:58 PM EasternExtended Trading$10.56 +0.08 (+0.72%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Zevra Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.04Beat/MissN/AOne Year Ago EPSN/AZevra Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$26.64 millionBeat/MissN/AYoY Revenue GrowthN/AZevra Therapeutics Announcement DetailsQuarterQ3 2025Date11/11/2025TimeBefore Market OpensConference Call DateTuesday, November 11, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Zevra Therapeutics Earnings HeadlinesZevra Therapeutics (ZVRA): Evaluating Valuation Following Insider Buying and Sustained Revenue GrowthOctober 10, 2025 | finance.yahoo.comZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 6, 2025 | globenewswire.comNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Since then, we've seen a massive rollout of AI legislation, and the some of the stocks I recommended back then have doubled the market's return. Now I'm releasing a new "BUY LIST" to take advantage of Elon’s next launch, and giving away one name and ticker for free on this page here.October 14 at 2:00 AM | Altimetry (Ad)Zevra Therapeutics (NASDAQ:ZVRA) Downgraded to Hold Rating by Wall Street ZenOctober 5, 2025 | americanbankingnews.comCan Zevra Therapeutics (ZVRA) Turn Clinical Momentum Into Sustainable Competitive Advantage?September 29, 2025 | finance.yahoo.comZevra Therapeutics rises amid takeover speculationSeptember 25, 2025 | msn.comSee More Zevra Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zevra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zevra Therapeutics and other key companies, straight to your email. Email Address About Zevra TherapeuticsZevra Therapeutics (NASDAQ:ZVRA) discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.View Zevra Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff Concerns Upcoming Earnings ASML (10/15/2025)Abbott Laboratories (10/15/2025)Bank of America (10/15/2025)Kinder Morgan (10/15/2025)Morgan Stanley (10/15/2025)Progressive (10/15/2025)Prologis (10/15/2025)The PNC Financial Services Group (10/15/2025)CSX (10/16/2025)Interactive Brokers Group (10/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
